aTYR PHARMA INC (ATYR) stock
ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.99−0.25 (-4.77%)
Close on Nov 17, 2026Market cap $489.46MP/E –Yield –
aTYR PHARMA price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
aTYR PHARMA's price to sales ratio was 10.4× on Apr 30, 2026, against 281.5× a year earlier. Over the last 3 years it ranged from 3.5× to 495.2×, with a median of 8.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 10.4× | +0.3 |
| 2025 | Dec 31, 2025 | 10.1× | −392.1 |
| 2024 | Oct 31, 2024 | 402.2× | +394.5 |
| 2023 | Dec 29, 2023 | 7.7× | +3.4 |
| 2021 | Apr 30, 2021 | 4.3× | −0.3 |
| 2020 | Dec 31, 2020 | 4.5× | – |
See a number that looks wrong?